详情页 - 河北医科大学第四医院机构库

资源类型：

文章类型：

作者：

Shi, Yuankai[1] * ; Su, Hang[2] ; Song, Yongping[3] ; Jiang, Wenqi[4] ; Sun, Xiuhua[5] ; Qian, Wenbin[6] ; Zhang, Wei[7] ; Gao, Yuhuan[8] ; Jin, Zhengming[9] ; Zhou, Jianfeng[10] ; Jin, Chuan[11] ; Zou, Liqun[12] ; Qiu, Lugui[13] ; Li, Wei[14] ; Yang, Jianmin[15] ; Hou, Ming[16] ; Zeng, Shan[17] ; Liu, Peng[18] ; Zhou, Hui[19] ; Li, Xiao[20] ;

机构： [1]Beijing Key Lab Clin Study Anticancer Mol Targete, Dept Med Oncol, Beijing, Peoples R China [2]Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Drugs, Beijing, Peoples R China [3]Peking Union Med Coll, Beijing, Peoples R China [4]Mil Chinese Peoples Liberat Army, Hosp 307, Beijing, Peoples R China [5]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China [6]Henan Canc Hosp, Zhengzhou, Peoples R China [7]Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China [8]Dalian Med Univ, Affiliated Hosp 2, Dalian, Peoples R China [9]Zhejiang Univ, Affiliated Hosp 1, Med Sch, Hangzhou, Peoples R China [10]Peking Union Med Coll Hosp, Beijing, Peoples R China [11]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China [12]Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China [13]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China [14]Guangzhou Med Univ, Canc Hosp Affiliated, Guangzhou, Peoples R China [15]Sichuan Univ, West China Hosp, Chengdu, Peoples R China [16]Chinese Acad Med Sci, Blood Inst, Tianjin, Peoples R China [17]Jilin Univ, Hosp 1, Changchun, Peoples R China [18]ChangHai Hosp, Shanghai, Peoples R China [19]Shandong Univ, Qilu Hosp, Jinan, Peoples R China [20]Cent South Univ, Xiangya Hosp, Changsha, Peoples R China [21]Innovent Biol Suzhou Co Ltd, Suzhou, Peoples R China

出处：

DOI：

ISSN：

语种：

被引次数：

WOS：

中科院分区：

出版当年[2018]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2018]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Beijing Key Lab Clin Study Anticancer Mol Targete, Dept Med Oncol, Beijing, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study)

文献详情